PipelineReview.com6h
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
MALVERN, PA, USA I January 16, 2025 I Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
PipelineReview.com4h
MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx. SEATTLE, WA, USA I January 15, 2025 I MalarVx, Inc., a clinical-stage vaccine company, is proud to ...
PipelineReview.com1d
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...
PipelineReview.com1d
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
CAMBRIDGE, MA, USA I January 15, 2025 I Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of ...
PipelineReview.com1d
Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic
EDINBURGH, UK I January 15, 2025 I Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced ...
PipelineReview.com2d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...
PipelineReview.com2d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
“We look forward to advancing CTIM-76 toward target dose levels in 2025,” commented Claudio Dansky Ullmann, M.D., Chief Medical Officer of Context.
PipelineReview.com2d
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea I January 14, 2025 I Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug ...
PipelineReview.com2d
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
In conjunction with the Series C financing, Umoja’s Board of Directors is pleased to welcome Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, as a new Board member.
PipelineReview.com3d
Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802
EDINBURGH, UK I January 14, 2025 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological ...
PipelineReview.com4d
GSK Enters Agreement to Acquire IDRx, Inc.
PLYMOUTH, MA, USA I January 13, 2025 I GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...
PipelineReview.com4d
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of ...